NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its first-quarter revenues declined 1 percent as it missed the consensus Wall Street estimates on the top and bottom line.

The Waltham, Mass.-based firm brought in total revenues of $505.4 million for the three months ended March 31, down from $510.9 million in Q1 2012 and below the Wall Street estimate of $532.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.